Slide 1: Orion Half-Yearly Report January─June 2016
Orion Half-Yearly Report January─June 2016 19 July 2016 Timo Lappalainen President & CEO
Slide 2: Forward-looking statements
This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of these strat
Slide 3: Sales developed strongly in first half of the year
Sales developed strongly in first half of the year • Net sales and operating profit were higher than in comparative period • Outlook estimate updated in June • Specialty Products maintained strong growth • In Europe generic competition to Stalevo extended more slowly than expected • Sales of other p
Slide 4: Key figures
Key figures H1/2015 H1/2016 H1/2015 H1/2016 515 535 0.88 0.92 0.67 0.56 157 164 Net sales, EUR Operating profit, Basic earnings per Cash flow per share million EUR million share, EUR before financial items, EUR +4% +4% +4% -16% 4 19 July 2016 Orion Half-Yearly Report January─June 2016
Slide 5: Breakdown of net sales
Breakdown of net sales Group’s net sales in H1/2016 were EUR 535 million By business division By market area 5% 3% 4% 14% 7% 30% 35% 7% 46% 32% 17% Proprietary Products Specialty Products Animal Health Finland Scandinavia Fermion Other Europe North America Contract manufacturing & other Orion Diagno
Slide 6: Business Reviews
Business Reviews
Slide 7: Pharmaceuticals business
Pharmaceuticals business H1/2015 H1/2016 Net sales split 509 EUR million H1/16 H1/15 Change % 486 Proprietary Products 185 172 +8% Specialty Products 246 223 +10% Animal Health 38 44 -13% Fermion 20 29 -29% 157 165 Contract manufacturing & other 19 19 -1% • Net sales excluding branded Parkinson’s dr
Slide 8: Best-selling pharmaceuticals H1/2016
Best-selling pharmaceuticals H1/2016 Net sales Change Product Indication EUR million vs. H1/15 Parkinson’s disease 72 -11% Asthma, COPD 32 +27% Intensive care sedative 28 +27% Acute decompensated heart 28 +7% failure Rheumatoid arthritis, 22 +161% inflammatory bowel diseases Animal sedatives 12 -25%
Slide 9: Orion clear market leader in Finland
Orion clear market leader in Finland Finnish human pharmaceuticals Finland’s biggest pharmaceutical market in H1/2016 companies in H1/2016 EUR million Wholesale, EUR million 160 143 140 1 071 120 Orion’s market +3% share 13% 1,106 100 80 Orion in Finnish human 60 61 pharmaceuticals market, 60 49 50
Slide 10: Specialty Products growing strongly in Scandinavia
Specialty Products growing strongly in Scandinavia Net sales in key market areas in Net sales Change H1/2016 (EUR million) H1/2016 vs. TOP 3 Products EUR million H1/2015 Vs. Scandinavia 22 +161% H1/15 42 +33% 10 -6% Vs. Finland 9 -14% H1/15 143 +8% • Remsima growth is expected to slow in second half
Slide 11: Parkinson's drugs
Parkinson’s drugs 60 Market shares of Orion’s MAT3/ MAT3/ branded Parkinson’s drugs 2016 2015 50 Finland 1) 14% 19% 40 Sweden 1) 7% 13% EUR million 30 Norway 1) 15% 15% Denmark 1) 5% 13% 20 Germany 2) 8% 12% 10 UK 2) 11% 12% 0 United States 2) 3) 2% 2% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2013
Slide 12: Easyhaler product family and Simdax
Easyhaler® product family and Simdax® Simdax 18 16 16 14 14 12 12 EUR million EUR million 10 10 8 8 6 6 4 4 2 2 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2013 2014 2015 16 2013 2014 2015 16 Others Bufomix Easyhaler Simdax 12 19 July 2016 Orion Half-Yearl
Slide 13: Dexdor intensive care sedative
dexdor® intensive care sedative European sedative market MAT3/2016* Dexdor sales Total market value EUR 527 million (+4%) 16 13% 14 7% 12 10 EUR million 14% 8 66% 6 4 Propofol EUR 348 million (+3%) 2 Midazolam EUR 74 million (-2%) 0 Dexmedetomidine EUR 38 million (+27%) Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2
Slide 14: Key clinical pharmaceutical development projects 1/2
Key clinical pharmaceutical development projects 1/2 Project Indication PHASE Registration Easyhaler® budesonide-formoterol 1) Asthma, COPD I II III Registration Easyhaler® salmeterol-fluticasone 2) Asthma, COPD I II III Prostate cancer ODM-201 (androgen receptor antagonist) 3) (nmCRPC) I II III Pro
Slide 15: Key clinical pharmaceutical development projects 2/2
Key clinical pharmaceutical development projects 2/2 Project Indication PHASE Registration ODM-104 (more effective COMT inhibitor) Parkinson’s disease I II ODM-203 (targeted FGFR+VEGFR inhibitor) Solid tumours I II ODM-204 (CYP17 enzyme and androgen receptor inhibitor) Prostate cancer I ODM-108 (neg
Slide 16: Diagnostics business
Diagnostics business • Operating profit decreased H1/2015 H1/2016 mainly due to decrease in net sales and products with lower 30 28 margins accounting for higher proportion of sales • QuikRead® tests remained the main product 5.6 4.4 • Launching of the first Orion GenRead® test system products conti
Slide 17: Outlook for 2016
Outlook for 2016 (updated on 15 June 2016) Net sales are estimated to be slightly higher than in 2015 Net sales (net sales were EUR 1,016 million in 2015). Operating profit excluding possible capital gains is Operating profit estimated to exceed EUR 270 million (operating profit was EUR 267 million
Slide 18: Orion Calendar 2016─2017
Orion Calendar 2016─2017 Interim Report January─September 2016 Tue 25 Oct 2016 Financial Statement Release for 2016 Wed 8 Feb 2017 Planned to be held on Annual General Meeting 2017 Wed 22 Mar 2017 Interim Report January─March 2017 Wed 26 Apr 2017 Half-Yearly Report January─June 2017 Wed 19 Jul 2017
Slide 19: Orion – Building well-being
GRION Building well-being